within Pharmacolibrary.Drugs.ATC.A;

model A08AA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.755,
    Cl             = 0.0021666666666666666,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0055,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0025,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A08AA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fenfluramine is an amphetamine derivative previously used as an appetite suppressant for the treatment of obesity. It acts as a serotonin-releasing agent. Due to its association with pulmonary hypertension and heart valve disease, fenfluramine was withdrawn from the market in most countries in the late 1990s. It has been re-approved in some regions for the treatment of Dravet syndrome, a rare form of epilepsy, under the branded name Fintepla.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult volunteers after oral administration; typical therapeutic dose.</p><h4>References</h4><ol><li><p> (2024). Comparison Table: Some oral antiseizure medications. <i>The Medical letter on drugs and therapeutics</i> 66(1708) e133–e140. DOI:<a href=&quot;https://doi.org/10.58347/tml.2024.1708b&quot;>10.58347/tml.2024.1708b</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39073881/&quot;>https://pubmed.ncbi.nlm.nih.gov/39073881</a></p></li><li><p>Gammaitoni, A, et al., &amp; Boyd, B (2018). The Lack of Effect of Food on the Pharmacokinetics of ZX008 (Fenfluramine Oral Solution): Results of a Single-dose, Two-period Crossover Study. <i>Clinical therapeutics</i> 40(8) 1338–1346. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2018.05.013&quot;>10.1016/j.clinthera.2018.05.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29941151/&quot;>https://pubmed.ncbi.nlm.nih.gov/29941151</a></p></li><li><p>Mittur, A, et al., &amp; Boyd, B (2024). Effect of Hepatic Impairment on the Pharmacokinetics of Fenfluramine and Norfenfluramine. <i>Journal of clinical pharmacology</i> 64(7) 887–898. DOI:<a href=&quot;https://doi.org/10.1002/jcph.2431&quot;>10.1002/jcph.2431</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38523492/&quot;>https://pubmed.ncbi.nlm.nih.gov/38523492</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A08AA02;
